Objective: To observe the effect of Decoction Ⅲ for improving renal function and pathology in rats with 5/6 nephrectomy and analyze its therapeutic mechanism for renal fibrosis in chronic kidney disease using network pharmacology combined with molecular docking.

Methods: Forty male SD rats were randomized into two groups to receive two-staged 5/6 nephrectomy (=30) or sham operation (=10), and 2 weeks after the final operation, serum creatinine level of the rats was measured. The rats with nephrectomy were further randomized into Decoction Ⅲ group, losartan group and model group for daily treatment with the corresponding drugs via gavage starting at 1 week after 5/6 nephrectomy. After 16 weeks of treatment, serum creatinine and urea nitrogen levels of the rats were measured, and HE staining and Western blotting were used to examine the changes in renal pathology and fibrosis-related factors. Network pharmacology combined with molecular docking study was performed to explore the therapeutic mechanism Decoction Ⅲ against renal fibrosis in chronic kidney disease, and Western blotting was used to verify the expressions of the core targets.

Results: Compared with those in the model group, the rats receiving 5/6 nephrectomy and Decoction Ⅲ treatment showed significantly reduced serum creatinine and urea nitrogen levels, lessened renal pathologies, and improvement of the changes in epithelial mesenchymal transition-related proteins. Network pharmacological analysis showed that the main active ingredients of Decoction Ⅲ were acacetin, apigenin, eupatilin, quercetin, kaempferol and luteolin, and the key targets included STAT3, SRC, CTNNB1, PIK3R1 and AKT1. Molecular docking study revealed that the active ingredients of Decoction Ⅲ had good binding activity to the key targets. Western blotting showed that in rats with 5/6 nephrectomy, treatment with Decoction Ⅲ obviously restored the protein expression of STAT3, PI3K, and AKT in renal tissue.

Conclusion: Decoction Ⅲ can reduce renal injury induced by 5/6 nephrectomy in rats, and its therapeutic effects are mediated possibly by its main pharmacologically active ingredients that alleviate renal fibrosis modulating multiple targets including STAT3, PIK3R1, and AKT1.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339302PMC
http://dx.doi.org/10.12122/j.issn.1673-4254.2023.06.07DOI Listing

Publication Analysis

Top Keywords

decoction Ⅲ
36
5/6 nephrectomy
24
renal fibrosis
16
fibrosis chronic
12
chronic kidney
12
kidney disease
12
network pharmacology
12
molecular docking
12
serum creatinine
12
western blotting
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!